Synmosa Biopharma (4114) — Cash Flow Reinvestment Rate
Synmosa Biopharma (4114) has a Cash Flow Reinvestment Rate of 5.31x as of December 2025, reinvesting NT$986.18 Million (capex NT$59.46 Million plus investments NT$926.72 Million) from operating cash flow of NT$185.72 Million. See 4114 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Synmosa Biopharma Cash Flow Reinvestment Rate (2015–2025)
Historical reinvestment intensity for Synmosa Biopharma across 9 annual periods. For the full cash flow conversion analysis, see 4114 cash flow conversion.
Annual Cash Flow Reinvestment Rate for Synmosa Biopharma (2015–2025)
Year-by-year capital reinvestment analysis for Synmosa Biopharma. See Synmosa Biopharma (4114) financial flexibility to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.64x | NT$676.44 Million | NT$411.57 Million | NT$281.13 Million | ▲ +294.7% |
| 2024 | 0.42x | NT$325.05 Million | NT$780.62 Million | NT$269.65 Million | ▼ -78.4% |
| 2023 | 1.93x | NT$987.64 Million | NT$511.93 Million | NT$269.77 Million | ▲ +437.5% |
| 2022 | 0.36x | NT$226.22 Million | NT$630.25 Million | NT$129.29 Million | ▲ +63.6% |
| 2021 | 0.22x | NT$97.47 Million | NT$444.29 Million | NT$93.06 Million | ▼ -77.2% |
| 2020 | 0.96x | NT$244.96 Million | NT$254.40 Million | NT$154.41 Million | ▼ -97.3% |
| 2018 | 35.49x | NT$567.76 Million | NT$16.00 Million | NT$314.43 Million | ▲ +473.8% |
| 2016 | 6.19x | NT$1.46 Billion | NT$236.48 Million | NT$423.92 Million | ▼ -66.2% |
| 2015 | 18.30x | NT$431.85 Million | NT$23.60 Million | NT$369.26 Million | — |